Galecto’s Myelofibrosis Candidate Reduces Bone Marrow Fibrosis
Galecto Inc (NASDAQ:GLTO) announced results from a planned intermediate assessment of its ongoing MYLOX-1 Phase 2a trial of GB2064 for myelofibrosis.…
Regeneron-Sanofi’s Flagship Dupixent Becomes First FDA-Approved Treatment For Prurigo Nodularis
The FDA approved Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis. With…
Idera Pharma Acquires Rare Disease Player, Names New CEO
Idera Pharmaceuticals Inc (NASDAQ: IDRA) acquired Aceragen Inc, a privately-held biotechnology company focused on rare, orphan pulmonary, and rheumatic diseases.
Aligos Co-Founders File Complaint Against Johnson & Johnson Alleging Fraud
Aligos Therapeutics Inc (NASDAQ:ALGS) has filed a response to the complaint of and counterclaims against Janssen Biopharma. In November 2014, Johnson…
Atara Biotherapeutics to Receive Additional Near-Term Milestone Under Updated Tab-cel Commercialization Pact
Atara Biotherapeutics Inc (NASDAQ:ATRA) announced an update to its existing collaboration agreement with Pierre Fabre for the commercialization of tabelecleucel (tab-cel) for Epstein-Barr…
Gilead’s Investigation Reveals Two Kingpins Directly Associated With Fake HIV Medications Scheme
U.S. District Judge Ann Donnelly has ordered to freeze several assets related to people and entities accused of operating a U.S. supply chain that distributes counterfeit bottles of Gilead Sciences Inc's (NASDAQ: GILD) HIV drugs.
Amazon Unveils First Of Its Kind Bedside Sleep Tracker: Checkout Features
Amazon.com Inc (NASDAQ:AMZN) announced a contactless gadget that can monitor people’s sleep. The online retailer said its $139.99 sleep gadget, dubbed…
Cathie Wood Sells $2.8M In Healthcare Stock Buoyed By Amazon-Linked Rumors
Cathie Wood-led Ark Investment Management on Wednesday sold 96,746 shares of Signify Health Inc. (NYSE: SGFY), estimated to be valued at around $2.8 million.
Amid Challenging Backdrop, This Analyst Previews Teladoc Health’s Upcoming Q3 Earnings
RBC Capital Markets has cut the price target for Teladoc Health Inc (NYSE:TDOC) from $53 to $35 but reiterates the Outperform rating.…
PepGen’s Duchenne Candidate Has Potential For Greater Exon Skipping Capabilities At Lower Doses Versus Sarepta’s Candidate, Says Analyst
PepGen Inc (NASDAQ:PEPG) reported data from PGN-EDO51’s SAD study in adult healthy volunteers that suggest best-in-class exon skipping capabilities. SVB notes…